At the J.P. Morgan Healthcare conference, Lupin Pharmaceuticals, a subsidiary of India-based Lupin Limited, announced biosimilar development plans for the company.
At the J.P. Morgan Healthcare conference, Lupin Pharmaceuticals, a subsidiary of India-based Lupin Limited, announced biosimilar development plans for the company.
Lupin said that it is setting a target date to file regulatory applications for biosimilar etanercept (referenced on Amgen’s Enbrel) in the first quarter of 2019’s fiscal year in Europe, and in the third quarter of 2020’s fiscal year in the United States.
Looking farther in Lupin’s biosimilar pipeline, ranibizumab is currently in phase 1 clinical trials, while pegfilgrastim, filgrastim, denosumab, pertuzumab, and afliberept are all in early stages of development.
Lupin also discussed its goal of putting a stronger emphasis on addressing the $54 billion complex generic drugs market as it tries to set itself apart from the growing competition around branded drugs. In this respect, it is focusing efforts on developing its inhaled drug pipeline, worth $17 billion, in the next 3 years. Lupin also announced that it is in discussions with the FDA to explore opportunities to accelerate the development timeline for such programs. Lupin expects its complex generic portfolio to begin contributing to its yearly earnings growth starting in fiscal years 2018 to 2020.
The company also said that it is focusing on getting 2 of its plants, located in Goa and Indore, up to code after they received warning letters from the FDA in November 2017 for deviation in good manufacturing practices.
Issues observed include failure to thoroughly investigate unexplained discrepancies or failures of a batch or any of its components to meet any specifications and failure to establish appropriate time limits for the completion of each phase of production to assure the quality of the drug product.
In order to become compliant, the FDA has recommended that a current good manufacturing practice consultant be hired to comprehensively assess the manufacturing processes and laboratory systems.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.